Master Alliance Provisions Guide (MAPGuide)

All Agreements

(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Agreement
Aridis-PATH Vaccine Formulation Agreement
2007
Biotechnology company
Product development partnership
Vaccine
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.equitable-access.aridis-path-vaccine-formulation-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1190
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-2/
            [children] => 
        )

    [access-to-medicines.equitable-access.aridis-path-vaccine-formulation-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1193
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-3/
            [children] => 
        )

    [access-to-medicines.pricing.aridis-path-vaccine-formulation-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 100
            [slug] => pricing
            [title] => Affordable or reasonable pricing
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Affordable or reasonable pricing
            [provision_id] => 1193
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.aridis-path-vaccine-formulation-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1240
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1176
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [ip-ownership.protection-results.aridis-path-vaccine-formulation-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1160
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-8/
            [children] => 
        )

    [ip-ownership.sublicensee.aridis-path-vaccine-formulation-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 108
            [slug] => sublicensee
            [title] => Sublicenses
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Sublicenses
            [provision_id] => 1176
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement/
            [children] => 
        )

    [liability.limitation-of-liability.aridis-path-vaccine-formulation-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1275
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-5/
            [children] => 
        )

    [term-and-termination.effect-of-termination.aridis-path-vaccine-formulation-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 1284
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-7/
            [children] => 
        )

    [term-and-termination.term-of-agreement.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.aridis-path-vaccine-formulation-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1283
            [provision_permalink] => https://ghiaa.org/provision_document/aridis-path-vaccine-formulation-agreement-6/
            [children] => 
        )

)
AUTM Model Inter-Institutional Agreement
2015
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.benefit-revenue-sharing.autm-model-iia-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit/revenue sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit/revenue sharing
            [provision_id] => 1182
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-3/
            [children] => 
        )

    [consortium-structure. .autm] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1291
            [provision_permalink] => https://ghiaa.org/provision_document/autm/
            [children] => 
        )

    [information-sharing.confidentiality.autm-model-iia-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1243
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-5/
            [children] => 
        )

    [ip-ownership.exceptions-ip-ownership.autm-model-iia-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 93
            [slug] => exceptions-ip-ownership
            [title] => Exceptions or limitations to the IP ownership rules
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exceptions or limitations to the IP ownership rules
            [provision_id] => 1186
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.autm-model-iia-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1182
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-3/
            [children] => 
        )

    [ip-ownership.protection-results.autm-model-iia] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1164
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia/
            [children] => 
        )

    [liability.limitation-of-liability.autm-model-iia-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1273
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-6/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Warranties
            [provision_id] => 1259
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-9/
            [children] => 
        )

    [term-and-termination.term-of-agreement.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.autm-model-iia-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1280
            [provision_permalink] => https://ghiaa.org/provision_document/autm-model-iia-7/
            [children] => 
        )

)
AUTM Preliminary Patent Management Agreement
2013
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
  • No Issues
Boston University Startup Exclusive License
2012
Academic institution
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.use-background-ip.bu-startup-exclusive-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1127
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license/
            [children] => 
        )

    [liability.limitation-of-liability.bu-startup-exclusive-license-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1272
            [provision_permalink] => https://ghiaa.org/provision_document/bu-startup-exclusive-license-2/
            [children] => 
        )

)
CARB-X Research Subaward Agreement (for-profit)
2019
Funder
General Industry
Device
Diagnostic
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.equitable-access.carb-x-research-subaward-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1187
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-2/
            [children] => 
        )

    [ip-ownership.access-results.carb-x-research-subaward-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1173
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement/
            [children] => 
        )

    [ip-ownership.exploitation-results.carb-x-research-subaward-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1173
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement/
            [children] => 
        )

    [open-science.open-sciences.carb-x-research-subaward-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1218
            [provision_permalink] => https://ghiaa.org/provision_document/carb-x-research-subaward-agreement-3/
            [children] => 
        )

)
CAVD Data & Materials Sharing Agreement
2006
Academic institution
Funder
General Industry
Government
Other nonprofit
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.cavd-data-materials-sharing-agreement-2-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1250
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2-2/
            [children] => 
        )

    [information-sharing.confidentiality.cavd-data-materials-sharing-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1251
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-3/
            [children] => 
        )

    [information-sharing.confidentiality.gates-foundation-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1254
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-data-materials-sharing-agreement-4/
            [children] => 
        )

    [information-sharing.data-management.cavd-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1231
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-4/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.cavd-data-materials-sharing-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1251
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-3/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.gates-foundation-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1254
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-data-materials-sharing-agreement-4/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.cavd-data-materials-sharing-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 1231
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-4/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.cavd-data-materials-sharing-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1109
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.cavd-data-materials-sharing-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1134
            [provision_permalink] => https://ghiaa.org/provision_document/cavd-data-materials-sharing-agreement-2/
            [children] => 
        )

)
CEPI CfP3i Template Funding Agreement
2018
Funder
Vaccine
Preclinical
Early clinical (through Phase 2)
Array
(
    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1203
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-3/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1204
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-5/
            [children] => 
        )

    [access-to-medicines.equitable-access.cepi-cfp3i-template-funding-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1202
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-6/
            [children] => 
        )

    [access-to-medicines.public-health-licenses.cepi-cfp3i-template-funding-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 107
            [slug] => public-health-licenses
            [title] => Public health licenses
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Public health licenses
            [provision_id] => 1205
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-4/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.cepi-cfp3i-template-funding-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit/revenue sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit/revenue sharing
            [provision_id] => 1203
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-results.cepi-cfp3i-template-funding-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1159
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-7/
            [children] => 
        )

    [ip-ownership.protection-results.cepi-cfp3i-template-funding-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 996
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfp3i-template-funding-agreement-8/
            [children] => 
        )

    [open-science.open-data.cepi-cfpi3-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1221
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement/
            [children] => 
        )

    [open-science.open-data.cepi-cfpi3-template-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1222
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement-2/
            [children] => 
        )

    [open-science.open-sciences.cepi-cfpi3-template-funding-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1222
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement-2/
            [children] => 
        )

    [open-science.publication.cepi-cfpi3-template-funding-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1221
            [provision_permalink] => https://ghiaa.org/provision_document/cepi-cfpi3-template-funding-agreement/
            [children] => 
        )

)
Ebola WHO-Manufacturer LOA (Annex)
2015
Multilateral organization
Drug
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [information-sharing. .ebola-who-manufacturer-loa-annex] => GHIAA2019\IssueItem Object
        (
            [ID] => 49
            [slug] => information-sharing
            [title] => Information sharing & data safety
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Information sharing & data safety
            [provision_id] => 1227
            [provision_permalink] => https://ghiaa.org/provision_document/ebola-who-manufacturer-loa-annex/
            [children] => 
        )

    [information-sharing.confidentiality.ebola-who-manufacturer-loa-annex] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1227
            [provision_permalink] => https://ghiaa.org/provision_document/ebola-who-manufacturer-loa-annex/
            [children] => 
        )

)
EDCTP2 Policy on Clinical Trials
2018
Funder
Device
Diagnostic
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Array
(
    [open-science.open-data.edctp2-policy-on-clinical-trials-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1215
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials-2/
            [children] => 
        )

    [open-science.open-data.edctp2-policy-on-clinical-trials-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1217
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials-3/
            [children] => 
        )

    [open-science.open-sciences.edctp2-policy-on-clinical-trials] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1216
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials/
            [children] => 
        )

    [open-science.open-sciences.edctp2-policy-on-clinical-trials-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1215
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials-2/
            [children] => 
        )

    [open-science.publication.edctp2-policy-on-clinical-trials] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1216
            [provision_permalink] => https://ghiaa.org/provision_document/edctp2-policy-on-clinical-trials/
            [children] => 
        )

)
Funder Development Partnering Agreement
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.funder-development-partnering-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1199
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-7/
            [children] => 
        )

    [access-to-medicines.equitable-access.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1201
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
            [children] => 
        )

    [access-to-medicines.equitable-access.funder-development-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1200
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-9/
            [children] => 
        )

    [access-to-medicines.funder-step-in.funder-development-partnering-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 103
            [slug] => funder-step-in
            [title] => Funder step-in rights
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Funder step-in rights
            [provision_id] => 1201
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-8/
            [children] => 
        )

    [access-to-medicines.outbreak-preparedness.funder-development-partnering-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 102
            [slug] => outbreak-preparedness
            [title] => Outbreak preparedness
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Outbreak preparedness
            [provision_id] => 1198
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-6/
            [children] => 
        )

    [business-model.benefit-revenue-sharing.funder-development-partnering-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 66
            [slug] => benefit-revenue-sharing
            [title] => Benefit/revenue sharing
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Benefit/revenue sharing
            [provision_id] => 1200
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-9/
            [children] => 
        )

    [ip-ownership.access-results.funder-development-partnering-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1175
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.funder-development-partnering-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1184
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.funder-development-partnering-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1158
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-2/
            [children] => 
        )

    [ip-ownership.protection-results.funder-development-partnering-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1170
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.funder-development-partnering-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1139
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement/
            [children] => 
        )

    [liability.limitation-of-liability.funder-development-partnering-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1274
            [provision_permalink] => https://ghiaa.org/provision_document/funder-development-partnering-agreement-10/
            [children] => 
        )

)
Gates Foundation Open Access Policy
2015
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [open-science.open-data.1393] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1393
            [provision_permalink] => https://ghiaa.org/provision_document/1393/
            [children] => 
        )

    [open-science.open-sciences.1393] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1393
            [provision_permalink] => https://ghiaa.org/provision_document/1393/
            [children] => 
        )

    [open-science.publication.1393] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1393
            [provision_permalink] => https://ghiaa.org/provision_document/1393/
            [children] => 
        )

)
Gates Foundation Sample Terms & Conditions
2019
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1395
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement-2/
            [children] => 
        )

    [open-science.publication.gates-foundation-sample-terms-conditions-for-project-support-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1394
            [provision_permalink] => https://ghiaa.org/provision_document/gates-foundation-sample-terms-conditions-for-project-support-grant-agreement/
            [children] => 
        )

)
Gilead-Indian Manufacturers HCV License Agreement
2014
Multinational pharmaceutical company
Pharmaceutical manufacturer
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.access-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.ownership-results.gilead-hcv-license-agreement-with-indian-generic-manufacturers-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1145
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.gilead-hcv-license-agreement-with-indian-generic-manufacturers] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1137
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers/
            [children] => 
        )

    [liability.insurance.gilead-hcv-license-agreement-with-indian-generic-manufacturers-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 109
            [slug] => insurance
            [title] => Insurance
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Insurance
            [provision_id] => 1264
            [provision_permalink] => https://ghiaa.org/provision_document/gilead-hcv-license-agreement-with-indian-generic-manufacturers-3/
            [children] => 
        )

)
Global Access Commitment & Humanitarian License
2018
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

    [access-to-medicines.public-health-licenses.gates-global-access-commitment-and-humanitarian-license] => GHIAA2019\IssueItem Object
        (
            [ID] => 107
            [slug] => public-health-licenses
            [title] => Public health licenses
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Public health licenses
            [provision_id] => 1206
            [provision_permalink] => https://ghiaa.org/provision_document/gates-global-access-commitment-and-humanitarian-license/
            [children] => 
        )

)
IMI 1 Model Grant Agreement
2011
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.imi-2-model-grant-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1244
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-7/
            [children] => 
        )

    [ip-ownership.access-results.imi-1-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1171
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-1-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1111
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-1-model-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1147
            [provision_permalink] => https://ghiaa.org/provision_document/imi-1-model-grant-agreement-2/
            [children] => 
        )

)
IMI 2 JU Model Consortium Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .imi-2-joint-undertaking-model-consortium-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1307
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-11/
            [children] => 
        )

    [information-sharing.confidentiality.imi-2-joint-undertaking-model-consortium-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1306
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-10/
            [children] => 
        )

    [information-sharing.confidentiality.imi-2-joint-undertaking-model-consortium-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1245
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-5/
            [children] => 
        )

    [information-sharing.data-management.imi-2-joint-undertaking-model-consortium-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1257
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-6/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.imi-2-joint-undertaking-model-consortium-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1306
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-10/
            [children] => 
        )

    [information-sharing.material-transfer.imi-2-joint-undertaking-model-consortium-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 85
            [slug] => material-transfer
            [title] => Material transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Material transfer
            [provision_id] => 1237
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-4/
            [children] => 
        )

    [ip-ownership. .imi-2-joint-undertaking-model-consortium-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 48
            [slug] => ip-ownership
            [title] => IP ownership & licensing
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => IP ownership & licensing
            [provision_id] => 1311
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-12/
            [children] => 
        )

    [ip-ownership.exploitation-results.1305] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1305
            [provision_permalink] => https://ghiaa.org/provision_document/1305/
            [children] => 
        )

    [ip-ownership.exploitation-results.imi-2-joint-undertaking-model-consortium-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1179
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-2joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1309
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-2-joint-undertaking-model-consortium-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1304
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-9/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-joint-undertaking-model-consortium-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1166
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-joint-undertaking-model-consortium-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1132
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement/
            [children] => 
        )

    [liability.indemnity.imi-2-joint-undertaking-model-consortium-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1266
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-8/
            [children] => 
        )

    [liability.limitation-of-liability.imi-2-joint-undertaking-model-consortium-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1261
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-7/
            [children] => 
        )

    [liability.warranties.imi-2-joint-undertaking-model-consortium-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Warranties
            [provision_id] => 1261
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-joint-undertaking-model-consortium-agreement-7/
            [children] => 
        )

)
IMI 2 Model Grant Agreement
2017
Funder
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .imi-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1288
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2/
            [children] => 
        )

    [information-sharing.confidentiality.imi-2-model-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1253
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-8/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.imi-2-model-grant-agreement-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1253
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-8/
            [children] => 
        )

    [ip-ownership.access-results.imi-2-model-grant-agreement-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1310
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-11/
            [children] => 
        )

    [ip-ownership.access-results.imi-2-model-grant-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1172
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-4/
            [children] => 
        )

    [ip-ownership.exploitation-results.imi-2-model-grant-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1178
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.imi-2-model-grant-agreement-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1308
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-12/
            [children] => 
        )

    [ip-ownership.ownership-results.imi-2-model-grant-agreement-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1303
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-10/
            [children] => 
        )

    [ip-ownership.protection-results.imi-2-model-grant-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1165
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-model-grant-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1128
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-model-grant-agreement-%c2%a725-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1131
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-%c2%a725-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.imi-2-model-grant-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1129
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-2/
            [children] => 
        )

    [liability.limitation-of-liability.imi-2-model-grant-agreement-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1268
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-9/
            [children] => 
        )

    [open-science.open-data.imi-2-model-grant-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1211
            [provision_permalink] => https://ghiaa.org/provision_document/imi-2-model-grant-agreement-6/
            [children] => 
        )

)
Lambert Agreement D
2019
Academic institution
General Industry
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .lambert-agreement-d-13] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1293
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-13/
            [children] => 
        )

    [information-sharing.confidentiality.lambert-agreement-d-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1239
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-5/
            [children] => 
        )

    [information-sharing.confidentiality.lambert-agreement-d-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1252
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-6/
            [children] => 
        )

    [information-sharing.data-management.lambert-agreement-d-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1255
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-7/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.lambert-agreement-d-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1185
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-4/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.lambert-agreement-d-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1252
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-6/
            [children] => 
        )

    [ip-ownership.exploitation-results.lambert-agreement-d-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1177
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-3/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.lambert-agreement-d] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1107
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d/
            [children] => 
        )

    [ip-ownership.ownership-results.lambert-agreement-d-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1141
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.lambert-agreement-d-15] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1113
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-15/
            [children] => 
        )

    [liability.indemnity.lambert-agreement-d-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1262
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-10/
            [children] => 
        )

    [liability.limitation-of-liability.lambert-agreement-d-11] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1269
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-11/
            [children] => 
        )

    [liability.warranties.lambert-agreement-d-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 81
            [slug] => warranties
            [title] => Warranties
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Warranties
            [provision_id] => 1258
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-8/
            [children] => 
        )

    [open-science.open-sciences.lambert-agreement-d-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1214
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-14/
            [children] => 
        )

    [open-science.publication.lambert-agreement-d-14] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1214
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-14/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.lambert-agreement-d-12] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1281
            [provision_permalink] => https://ghiaa.org/provision_document/lambert-agreement-d-12/
            [children] => 
        )

)
Merck-BSC License Collaboration Agreement
2014
Biotechnology company
Multinational pharmaceutical company
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Array
(
    [information-sharing.confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1241
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-5/
            [children] => 
        )

    [information-sharing.confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1242
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6/
            [children] => 
        )

    [information-sharing.exceptions-confidentiality.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 83
            [slug] => exceptions-confidentiality
            [title] => Exceptions and limitations to the confidentiality obligations
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Exceptions and limitations to the confidentiality obligations
            [provision_id] => 1242
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-6/
            [children] => 
        )

    [information-sharing.technology-transfer.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 1235
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-4/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1112
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation/
            [children] => 
        )

    [ip-ownership.ownership-results.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1162
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3/
            [children] => 
        )

    [ip-ownership.protection-results.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1162
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-3/
            [children] => 
        )

    [ip-ownership.use-background-ip.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1140
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-2/
            [children] => 
        )

    [liability.indemnity.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1267
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-7/
            [children] => 
        )

    [liability.limitation-of-liability.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1276
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-8/
            [children] => 
        )

    [term-and-termination.effect-of-termination.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10] => GHIAA2019\IssueItem Object
        (
            [ID] => 72
            [slug] => effect-of-termination
            [title] => Effect of termination
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Effect of termination
            [provision_id] => 1287
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-10/
            [children] => 
        )

    [term-and-termination.term-of-agreement.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1285
            [provision_permalink] => https://ghiaa.org/provision_document/license-and-collaboration-agreement-between-merck-and-bioprotection-systems-corp-wholly-owned-subsidiary-of-newlink-genetic-corporation-9/
            [children] => 
        )

)
MPP-AbbVie License Agreement (LPV r)
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [ip-ownership.exploitation-results.mpp-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 92
            [slug] => exploitation-results
            [title] => Exploitation of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Exploitation of results
            [provision_id] => 1183
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-abbvie/
            [children] => 
        )

)
MPP-AbbVie Sublicense Agreement
2014
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [business-model. .mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 53
            [slug] => business-model
            [title] => Business model
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Business model
            [provision_id] => 1125
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2/
            [children] => 
        )

    [ip-ownership.sublicensee.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 108
            [slug] => sublicensee
            [title] => Sublicenses
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Sublicenses
            [provision_id] => 1120
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1120
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1125
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpps-license-agreement-with-abbvie] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1118
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-abbvie/
            [children] => 
        )

    [liability.indemnity.mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1313
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-sublicense-agreement-under-abbvie-mpp-license-agreement-3/
            [children] => 
        )

)
MPP-BMS Sublicense & Tech Transfer Agreement
2017
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [information-sharing.technology-transfer.mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 1229
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1124
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement/
            [children] => 
        )

    [liability.indemnity.mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1314
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-amended-and-restated-sublicense-and-technology-transfer-agreement-under-bms-mpp-license-agreement-2/
            [children] => 
        )

)
MPP-BMS-Aurobindo Sublicense Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Pharmaceutical manufacturer
Drug
Commercialization
Array
(
    [ip-ownership.use-background-ip.mpp-license-agreement-with-bms-aurobindo-pharma-ltd] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1122
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-bms-aurobindo-pharma-ltd/
            [children] => 
        )

)
MPP-Gilead License Agreement
2011
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [information-sharing.confidentiality.mpp-license-agreement-with-gilead-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1228
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-3/
            [children] => 
        )

    [information-sharing.confidentiality.mpp-license-agreement-with-gilead-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1249
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-4/
            [children] => 
        )

    [information-sharing.technology-transfer.mpp-license-agreement-with-gilead-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 1228
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-3/
            [children] => 
        )

    [ip-ownership.access-results.mpp-license-agreement-with-gilead-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1143
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-2/
            [children] => 
        )

    [ip-ownership.ownership-results.mpp-license-agreement-with-gilead-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1143
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.mpp-license-agreement-with-gilead] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1114
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead/
            [children] => 
        )

    [liability.indemnity.mpp-license-agreement-with-gilead-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1263
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-5/
            [children] => 
        )

    [liability.limitation-of-liability.mpp-license-agreement-with-gilead-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1270
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-gilead-6/
            [children] => 
        )

)
MPP-Merck License Agreement (Raltegravir)
2015
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
  • No Issues
MPP-Pfizer License Agreement (Sutezolid)
2019
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [access-to-medicines.equitable-access.mpp-license-agreement-with-pfizer-re-sutezolid] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1207
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-pfizer-re-sutezolid/
            [children] => 
        )

)
MPP-Univ. of Liverpool License Agreement
2015
Academic institution
Other nonprofit
Device
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [business-model.royalties-and-payments.mpps-license-agreement-with-university-of-liverpool] => GHIAA2019\IssueItem Object
        (
            [ID] => 70
            [slug] => royalties-and-payments
            [title] => Royalties & payments
            [parent] => 53
            [parent_slug] => business-model
            [parent_title] => Business model
            [display_title] => Business model | Royalties & payments
            [provision_id] => 1117
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-university-of-liverpool/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.mpps-license-agreement-with-university-of-liverpool] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1117
            [provision_permalink] => https://ghiaa.org/provision_document/mpps-license-agreement-with-university-of-liverpool/
            [children] => 
        )

)
MPP-ViiV License Agreement
2016
Multinational pharmaceutical company
Other nonprofit
Drug
Commercialization
Array
(
    [ip-ownership.use-background-ip.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1123
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults/
            [children] => 
        )

    [liability.indemnity.mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1315
            [provision_permalink] => https://ghiaa.org/provision_document/mpp-license-agreement-with-viiv-on-dolutegravir-for-adults-2/
            [children] => 
        )

)
NIH Model License Agreement for Use by Non-Profit
2017
Government
Other nonprofit
Product development partnership
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [ip-ownership.protection-results.nih-model-license-agreement-for-use-by-non-profit-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 90
            [slug] => protection-results
            [title] => Protection of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Protection of results
            [provision_id] => 1168
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit-2/
            [children] => 
        )

    [ip-ownership.use-background-ip.nih-model-license-agreement-for-use-by-non-profit] => GHIAA2019\IssueItem Object
        (
            [ID] => 88
            [slug] => use-background-ip
            [title] => Use of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Use of background IP
            [provision_id] => 1135
            [provision_permalink] => https://ghiaa.org/provision_document/nih-model-license-agreement-for-use-by-non-profit/
            [children] => 
        )

)
Redacted Collaboration Agreement
2016
Academic institution
General Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing. .redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 49
            [slug] => information-sharing
            [title] => Information sharing & data safety
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Information sharing & data safety
            [provision_id] => 1233
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
            [children] => 
        )

    [information-sharing.confidentiality.redacted-collaboration-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1248
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-6/
            [children] => 
        )

    [information-sharing.data-management.redacted-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 82
            [slug] => data-management
            [title] => Data management
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Data management
            [provision_id] => 1232
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-3/
            [children] => 
        )

    [information-sharing.information-sharing-information-sharing.redacted-collaboration-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 257
            [slug] => information-sharing-information-sharing
            [title] => Information sharing
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Information sharing
            [provision_id] => 1232
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-3/
            [children] => 
        )

    [information-sharing.material-transfer.redacted-collaboration-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 85
            [slug] => material-transfer
            [title] => Material transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Material transfer
            [provision_id] => 1238
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-5/
            [children] => 
        )

    [ip-ownership.ownership-results.redacted-collaboration-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1150
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement/
            [children] => 
        )

    [open-science.open-data.redacted-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1220
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-2/
            [children] => 
        )

    [open-science.open-sciences.redacted-collaboration-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1220
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-2/
            [children] => 
        )

    [open-science.publication.redacted-collaboration-agreement-4] => GHIAA2019\IssueItem Object
        (
            [ID] => 96
            [slug] => publication
            [title] => Publication
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Publication
            [provision_id] => 1233
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-4/
            [children] => 
        )

    [term-and-termination.term-of-agreement.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 76
            [slug] => term-of-agreement
            [title] => Term of agreement
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Term of agreement
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

    [term-and-termination.termination-and-withdrawal.redacted-collaboration-agreement-7] => GHIAA2019\IssueItem Object
        (
            [ID] => 74
            [slug] => termination-and-withdrawal
            [title] => Termination & withdrawal
            [parent] => 52
            [parent_slug] => term-and-termination
            [parent_title] => Term & termination
            [display_title] => Term & termination | Termination & withdrawal
            [provision_id] => 1282
            [provision_permalink] => https://ghiaa.org/provision_document/redacted-collaboration-agreement-7/
            [children] => 
        )

)
Ten Principles for Socially Responsible Licensing
2019
Academic institution
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [access-to-medicines.equitable-access.ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019] => GHIAA2019\IssueItem Object
        (
            [ID] => 101
            [slug] => equitable-access
            [title] => Equitable access
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Equitable access
            [provision_id] => 1210
            [provision_permalink] => https://ghiaa.org/provision_document/ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019/
            [children] => 
        )

    [access-to-medicines.policy-considerations.ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019] => GHIAA2019\IssueItem Object
        (
            [ID] => 104
            [slug] => policy-considerations
            [title] => Policy considerations
            [parent] => 46
            [parent_slug] => access-to-medicines
            [parent_title] => Access to medicines
            [display_title] => Access to medicines | Policy considerations
            [provision_id] => 1210
            [provision_permalink] => https://ghiaa.org/provision_document/ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019/
            [children] => 
        )

    [open-science.open-data.ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 98
            [slug] => open-data
            [title] => Open data
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open data
            [provision_id] => 1223
            [provision_permalink] => https://ghiaa.org/provision_document/ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2/
            [children] => 
        )

    [open-science.open-sciences.ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 97
            [slug] => open-sciences
            [title] => Open sciences
            [parent] => 47
            [parent_slug] => open-science
            [parent_title] => Open sciences & open data
            [display_title] => Open sciences & open data | Open sciences
            [provision_id] => 1223
            [provision_permalink] => https://ghiaa.org/provision_document/ten-principles-for-socially-responsible-licensing-by-netherlands-federation-of-university-medical-centers-june-2019-2/
            [children] => 
        )

)
WHO Mutual Confidential Disclosure Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.who-mutual-confidential-disclosure-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1247
            [provision_permalink] => https://ghiaa.org/provision_document/who-mutual-confidential-disclosure-agreement/
            [children] => 
        )

)
WHO Project Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .who] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1296
            [provision_permalink] => https://ghiaa.org/provision_document/who/
            [children] => 
        )

)
WHO Standard Framework MoU
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .who] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1296
            [provision_permalink] => https://ghiaa.org/provision_document/who/
            [children] => 
        )

    [ip-ownership.access-results.who-standard-framework-memorandum-of-understanding] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1156
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding/
            [children] => 
        )

    [ip-ownership.ownership-results.who-standard-framework-memorandum-of-understanding] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1156
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding/
            [children] => 
        )

    [liability.limitation-of-liability.who-standard-framework-memorandum-of-understanding-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 79
            [slug] => limitation-of-liability
            [title] => Limitation of liability/damage
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Limitation of liability/damage
            [provision_id] => 1271
            [provision_permalink] => https://ghiaa.org/provision_document/who-standard-framework-memorandum-of-understanding-2/
            [children] => 
        )

)
WHO Template Collaboration Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [consortium-structure. .who] => GHIAA2019\IssueItem Object
        (
            [ID] => 51
            [slug] => consortium-structure
            [title] => Consortium structure & management
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Consortium structure & management
            [provision_id] => 1296
            [provision_permalink] => https://ghiaa.org/provision_document/who/
            [children] => 
        )

    [information-sharing. .who-template-material-transfer-agreement-3] => GHIAA2019\IssueItem Object
        (
            [ID] => 49
            [slug] => information-sharing
            [title] => Information sharing & data safety
            [parent] => 0
            [parent_slug] => 
            [parent_title] => 
            [display_title] => Information sharing & data safety
            [provision_id] => 1226
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-3/
            [children] => 
        )

    [ip-ownership.access-results.template-collaboration-agreement-with-who] => GHIAA2019\IssueItem Object
        (
            [ID] => 91
            [slug] => access-results
            [title] => Access to results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Access to results
            [provision_id] => 1155
            [provision_permalink] => https://ghiaa.org/provision_document/template-collaboration-agreement-with-who/
            [children] => 
        )

    [ip-ownership.ownership-results.template-collaboration-agreement-with-who] => GHIAA2019\IssueItem Object
        (
            [ID] => 89
            [slug] => ownership-results
            [title] => Ownership of results
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of results
            [provision_id] => 1155
            [provision_permalink] => https://ghiaa.org/provision_document/template-collaboration-agreement-with-who/
            [children] => 
        )

)
WHO Template Material Transfer Agreement
2015
Multilateral organization
Device
Diagnostic
Drug
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Array
(
    [information-sharing.confidentiality.who-template-material-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 84
            [slug] => confidentiality
            [title] => Confidentiality
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Confidentiality
            [provision_id] => 1225
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-2/
            [children] => 
        )

    [information-sharing.material-transfer.who-template-material-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 85
            [slug] => material-transfer
            [title] => Material transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Material transfer
            [provision_id] => 1225
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-2/
            [children] => 
        )

    [information-sharing.material-transfer.who-template-material-transfer-agreement-5] => GHIAA2019\IssueItem Object
        (
            [ID] => 85
            [slug] => material-transfer
            [title] => Material transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Material transfer
            [provision_id] => 1236
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-5/
            [children] => 
        )

    [information-sharing.technology-transfer.who-template-material-transfer-agreement-2] => GHIAA2019\IssueItem Object
        (
            [ID] => 86
            [slug] => technology-transfer
            [title] => Technology transfer
            [parent] => 49
            [parent_slug] => information-sharing
            [parent_title] => Information sharing & data safety
            [display_title] => Information sharing & data safety | Technology transfer
            [provision_id] => 1225
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-2/
            [children] => 
        )

    [ip-ownership.ownership-background-ip.who-template-material-transfer-agreement] => GHIAA2019\IssueItem Object
        (
            [ID] => 87
            [slug] => ownership-background-ip
            [title] => Ownership of background IP
            [parent] => 48
            [parent_slug] => ip-ownership
            [parent_title] => IP ownership & licensing
            [display_title] => IP ownership & licensing | Ownership of background IP
            [provision_id] => 1108
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement/
            [children] => 
        )

    [liability.indemnity.who-template-material-transfer-agreement-6] => GHIAA2019\IssueItem Object
        (
            [ID] => 80
            [slug] => indemnity
            [title] => Indemnity / indemnification
            [parent] => 50
            [parent_slug] => liability
            [parent_title] => Liability
            [display_title] => Liability | Indemnity / indemnification
            [provision_id] => 1265
            [provision_permalink] => https://ghiaa.org/provision_document/who-template-material-transfer-agreement-6/
            [children] => 
        )

)